We confirmed that several of these modulators were able to reduce the α-synuclein aggregation, including Ambroxol, and recover the movement defect in the worm model of PD, demonstrating this economical and simple methodology to screen candidate compounds for a positive impact on disease progression. The gene discussed is SNCA; the disease is Parkinson disease.